L
Lawrence D. True
Researcher at University of Washington
Publications - 321
Citations - 34128
Lawrence D. True is an academic researcher from University of Washington. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 72, co-authored 289 publications receiving 29134 citations. Previous affiliations of Lawrence D. True include United States Department of Veterans Affairs & Emory University.
Papers
More filters
Journal ArticleDOI
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort
Lisa F. Newcomb,Lisa F. Newcomb,Ian M. Thompson,Hilary Boyer,James D. Brooks,Peter R. Carroll,Matthew R. Cooperberg,Atreya Dash,William J. Ellis,Ladan Fazli,Ziding Feng,Martin E. Gleave,Priya Kunju,Raymond S. Lance,Jesse K. McKenney,Maxwell V. Meng,Marlo M. Nicolas,Martin G. Sanda,Jeffry P. Simko,Alan So,Maria S. Tretiakova,Dean A. Troyer,Lawrence D. True,Funda Vakar-Lopez,Jeff Virgin,Andrew A. Wagner,John T. Wei,Yingye Zheng,Peter S. Nelson,Daniel W. Lin,Daniel W. Lin +30 more
TL;DR: Most men remain on active surveillance at 5 years without adverse reclassification or adverse pathology at surgery, supporting the need for approaches that improve the prediction of this outcome.
Journal ArticleDOI
125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.
Kent E. Wallner,Kent E. Wallner,Kent E. Wallner,Gregory S. Merrick,Lawrence D. True,Steven Sutlief,Steven Sutlief,William Cavanagh,Wayne M. Butler +8 more
TL;DR: The 3-year actuarial biochemical control rates for low early-stage prostate cancer are similar after (125)I and (103)Pd, and the effect of the dosimetric parameters on biochemical control was most pronounced for ( 125)I, but also apparent for (103]Pd.
Journal ArticleDOI
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.
Lauren Brady,Michelle Kriner,Ilsa Coleman,Colm Morrissey,Martine Roudier,Lawrence D. True,Roman Gulati,Stephen R. Plymate,Zoey Zhou,Brian Birditt,Rhonda Meredith,Gary K. Geiss,Margaret L. Hoang,Joseph M. Beechem,Peter S. Nelson,Peter S. Nelson +15 more
TL;DR: In this article, the authors used digital spatial profiling (DSP) technology to quantitate transcript and protein abundance in spatially-distinct regions of metastatic prostate cancer (mPCs).
Journal ArticleDOI
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients
TL;DR: The results of the first detailed quantitative analysis of PSMA mRNA expression in patient's tissues demonstrate that PSMA and the 3 PSMA splice variants are expressed in normal, benign, cancerous and metastatic prostate cancer.
Journal ArticleDOI
New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Kiril Trpkov,Ondrej Hes,Sean R. Williamson,Adebowale J. Adeniran,Abbas Agaimy,Reza Alaghehbandan,Mahul B. Amin,Pedram Argani,Ying-Bei Chen,Liang Cheng,Jonathan I. Epstein,John C. Cheville,Eva Compérat,Isabela Werneck da Cunha,Jennifer B. Gordetsky,Sounak Gupta,Huiying He,Michelle S. Hirsch,Peter A. Humphrey,Payal Kapur,Fumiyoshi Kojima,José I. López,Fiona Maclean,Cristina Magi-Galluzzi,Jesse K. McKenney,Rohit Mehra,Santosh Menon,George J. Netto,Christopher G. Przybycin,Priya Rao,Qiu Rao,Victor E. Reuter,Rola Saleeb,Rajal B. Shah,Steven C. Smith,Satish K. Tickoo,Maria S. Tretiakova,Lawrence D. True,Virginie Verkarre,Sara E. Wobker,Ming Zhou,Anthony J. Gill,Anthony J. Gill,Anthony J. Gill +43 more
TL;DR: The authors in this article reviewed recent advances in renal neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide an update on existing entities, including diagnostic criteria, molecular correlates, and updated nomenclature.